N1 Life and XtalPi Establish Non-Invasive Ocular Drug Delivery Platform for Nucleic Acid and Macromolecular Therapeutics

　　China Securities News (reported by Wang Ke) — On August 8, it was reported that N1 Life, Inc. (Suzhou) (referred to as N1 Life) and XtalPi (2228.HK) have reached a technical collaboration. The partnership will combine peptide molecule design with artificial intelligence (AI), high-throughput, and automated screening platforms to develop safer and more efficient drug delivery systems for macromolecular drugs and nucleic acid drugs targeting ophthalmic diseases. Both parties will jointly utilize N1 Life’s peptide carrier library, developed over years of research in collaboration with Stanford University, along with XtalPi's well-established peptide molecule design and screening platform, to achieve AI-powered platform-based drug delivery peptide carrier designs. This collaboration aims to enhance the drugability of macromolecular drugs such as RNA and accelerate the development of novel ophthalmic drugs.

In this collaboration, XtalPi will utilize its mRNA-encoded peptide library (mRNA Display) and screening technology to co-design a peptide library with N1 Life. Based on N1 Life's established tissue delivery screening model, they will perform high-throughput screening to construct a peptide delivery system with strong targeting ability, good stability, and high delivery efficiency. This aims to address the key challenges of intravitreal macromolecule drug delivery and explore more advanced and efficient R&D models for macromolecule drug delivery in more disease areas, paving new development pathways for drugs that are otherwise difficult to formulate.

According to statistics, the global large-molecule drug market size exceeded 300 billion US dollars in 2023 and is expected to reach 500 billion US dollars by 2030. Meanwhile, with the intensification of global aging and the rising incidence of ophthalmic diseases, the demand for highly effective ophthalmic drugs continues to grow. The ophthalmic drug market is projected to reach 23.4 billion US dollars by 2030.